Live Breaking News & Updates on Biotechnology Space

Stay updated with breaking news from Biotechnology space. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Laurus Labs Q4 PAT gallops 170% to Rs 297 cr


The drug maker s consolidated net profit soared 170% to Rs 297 crore on 68% surge in net sales to Rs 1,412 crore in Q4 FY21 over Q4 FY20.
On a consolidated basis, EBITDA grew 147% to Rs 477 crore in Q4 FY21 over Q4 FY20 while EBITDA margins stood at 34%. The board approved an interim dividend amounting to Re 0.80 per share.
The net profit soared 286% to Rs 984 crore on 70% surge in net sales to Rs 4,814 crore in the year ended March 2021 (FY21) over the year ended March 2020 (FY20). EBITDA grew 176% to Rs 1,573 crore in FY21 over FY20 while EBITDA margins stood at 33%.
The Reaseach and Development (R&D) expense stood at Rs 184 crore in FY21 which is 4% of its sales in FY21. The Generic FDF segment recorded a sale of Rs 430 crore, which is 30% of the contribution in Q4 and Rs 1,664 crore, 35% contribution in FY21. ....

Satyanarayana Chava , Laurus Bio , America Europe , Richcore Life Sciences Pvt , Drug Master Files , Active Pharmaceutical Ingredients , Laurus Labs , Richcore Life Sciences Pvt Limited , North America , Custom Synthesis , Capital Market , Harmaceuticals Nec , Recombinant Products , Harmaceutical Manufacturing , Biotechnology Space , Satyanarayana Chava , Richcore Life Sciences Pvt Limited , United States , North America , Chief Executive Officer , சத்தியநாராயணா சாவா , லாரஸ் உயிர் , அமெரிக்கா யூரோப் , மருந்து குரு கோப்புகள் , செயலில் மருந்து பொருட்கள் , லாரஸ் ஆய்வகங்கள் ,